57 research outputs found
Spontaneous Bacterial Peritonitis in Patients with Hepatitis B Virus-Related Liver Cirrhosis: Community-Acquired versus Nosocomial
Effect of Lacidipine on Blood Pressure and Endothelial Function in Mild-to-Moderate Essential Hypertension Patients With Diabetes in Korea
Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
Background/AimsCarnitine and vitamin complex (Godex®) is widely used in patients with chronic liver disease who show elevated liver enzyme in South Korea. The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients.Methods130 treatment-naïve patients with CHB were enrolled from 13 sites. The patients were randomly selected to the entecavir and the complex of entecavir and carnitine. The primary endpoint of the study is ALT normalization level after 12 months.ResultsAmong the 130 patients, 119 patients completed the study treatment. The ALT normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001). ALT normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019). The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was. Quantification of HBsAg level was not different from the monotherapy to combination at 12 months. Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment.ConclusionsALT normalization rate was higher in carnitine complex combination group than entecavir group in CHB. Combination group was faster than entecavir mono-treatment group on ALT normalization rate. HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment
Establishment and operation of industrial accident prevention system
노트 : Government Publications Registration Number 11-7003625-000055-0
2012 경제발전경험모듈화사업 : 산업재해 예방제도 구축 및 운영
Chapter 1 OSH and Labor Market in Korea
1. Change in the Labor Market
2. Importance of OSH
Chapter 2 Introduction and Development of Prevention System
1. Advances in OSH Regulations
2. Advances in Administrative System on OSH
3. Implementation of Various Accident Prevention Plans
4. Establishment of KOSHA
Chapter 3 Statistics System and Trends on OSH
1. Introduction of Statistics System on Industrial Accidents
2. Statistics on Industrial Accidents
Chapter 4 Application and Implementation of OSH Policy
1. Laying the Foundation for OSH
2. Technical Guidance and Support Program that Bring Changes to Worksites
3. Accident Prevention in Construction Industry through Participation and Support
4. Improving Work Environment and Health Management for Workers
5. Securing Professional Knowledge and Capacity in OSH
6. Enhancing the Level of Expertise in OSH Training
7. Raising Safety Awareness at the National Level
8. Advancement and Globalization of OSH
Chapter 5 Assessment and Application of Industrial Accident Prevention System
1. Laws and Regulations on Industrial Accident Prevention and Relevant Administrative System ·
2. Establishment and Implementation of Industrial Accident Prevention Strategies
3. Introduction and Operation of Statistics System on Industrial Accidents
4. Establishment and Operation of an Independent Organization Specializing in Industrial Accident Prevention
Chapter 6 Conclusio
- …